The British Society for Rheumatology (BSR) Biologics Register in Ankylosing Spondylitis is funded by the BSR and they have receive funds for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts and can provide comments but have no input into determining the topics for analysis, publication and no input into the work involved in this analysis. This analysis is part-funded by Arthritis Research UK (Grant No: 21378)Peer reviewedPublisher PD

Atzeni, Fabiola

Barnish, Maxwell S

Haywood, Kirstie L

Jones, Gareth T

MacFarlane, Gary J

Martin, Kathryn R

Packham, Jonathan

Pathan, Ejaz

Siebert, Stefan

Arthritis & Rheumatology

English

Objective: To estimate the proportion of patients with axial spondyloarthritis (axSpA) who meet criteria for fibromyalgia (FM) and to characterise such patients.



Methods: The British Society for Rheumatology Biologics Register of Ankylosing Spondylitis (BSRBR-AS) recruits two cohorts of patients who meet ASAS criteria for axSpA across 83 centres in the United Kingdom. Patients are either newly starting (biologic cohort) or naïve (non-biologic cohort) to biologic therapy and are followed prospectively. At recruitment and follow-up, clinical information and measurements are recorded, while patients complete the 2011 research criteria for FM, assessments of disease activity and impact.



Results: 1504 patients (68% male) were eligible for the current analysis of whom 311 (20.7%) met criteria for FM. Prevalence was similar among those who fulfilled modified New York (mNY) criteria (19.7%), and ASAS imaging but not mNY criteria (25.2%), but lower among those who only fulfilled ASAS clinical criteria (9.5%). Patients who met FM criteria reported significantly worse disease activity, function, global severity scores, quality of life and were more likely to have moderate/severe levels of mood disorder and clinically important fatigue. They reported work impairment around half the time. Meeting FM criteria was not related to elevated C-reactive protein, or most extra-spinal manifestations, but was associated with a higher likelihood of having received biologic therapy.



Conclusion: Developing management approaches that address the significant unmet needs of the 1 in 5 axSpA patients who meet criteria for FM should be a research priority

Macfarlane, Gary J.

Barnish, Maxwell S.

Martin, Kathryn R.

Haywood, Kirstie L.

Jones, Gareth T.

Enlighten

The co-occurrence and characteristics of patients with axial spondyloarthritis who meet criteria for fibromyalgia: results from a UK national register (BSRBR-AS)

Gary J. Macfarlane

Maxwell S. Barnish

Ejaz Pathan

Kathryn R. Martin

Kirstie L. Haywood

Stefan Siebert

Jonathan Packham

Fabiola Atzeni

Gareth T. Jones

Crossref

Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia

Enlighten: Publications

The British Society for Rheumatology (BSR) Biologics Register in Ankylosing Spondylitis is funded by the BSR and they have receive funds for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts and can provide comments but have no input into determining the topics for analysis, publication and no input into the work involved in this analysis. This analysis is part-funded by Arthritis Research UK (Grant No: 21378)Peer reviewe

The Open University

Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia : Results From a UK National Register

https://aura.abdn.ac.uk/bitstream/2164/9515/1/Co_Occurrence_and_Characteristics_of_Patients_With_Axial_Spondyloarthritis_Who_Meet_Criteria_for_Fibromyalgia.pdf

Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia : Results From a UK National Register

Abstract

Similar works

Full text

Available Versions

Enlighten

Crossref

Enlighten: Publications

The Open University